Aurélie Wiedemann

Aurélie Wiedemann

Auto-generated profile, based on publicly available information

Aurélie Wiedemann

Vaccine research Institute

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
AWAurelie Wiedemann
Aurelie Wiedemann
DDDavid Depoil
David Depoil
MFMustapha Faroudi
Mustapha Faroudi
SVSalvatore Valitutti
Salvatore Valitutti
A longstanding paradox in the activation of cytotoxic T lymphocytes (CTL) arises from the observation that CTL recognize and rapidly destroy target cells with exquisite sensitivity despite the fact that cytokine production requires sustained signaling at the immunological synapse. Here we solve this paradox by showing that CTL establish sustained synapses with targets offering strong antigenic stimuli and that these synapses persist after target cell death. Simultaneously, CTL polarize lytic granules toward different cells without discrimination regarding antigenic potential. Our results show that spatiotemporal uncoupling of immunological synapse and lytic granule secretion allows multiple killing and sustained signaling by individual CTL. This unique mechanism of responding to multiple contacts provides remarkable efficiency to CTL function.

1 July 2021 in iScience
Verified
Journal Article
Open access
YLYves Lévy
Yves Lévy
AWAurélie Wiedemann
Aurélie Wiedemann
BHBoris Hejblum
Boris Hejblum
MDMélany Durand
Mélany Durand
CLCécile Lefebvre
Cécile Lefebvre
RTRodolphe Thiébaut
Rodolphe Thiébaut
The identification of COVID-19 patients with high-risk of severe disease is a challenge in routine care. We performed cell phenotypic, serum and RNA-seq gene expression analyses in severe hospitalized patients (n = 61). Relative to healthy donors, results showed abnormalities of 27 cell populations and an elevation of 42 cytokines, neutrophil chemo-attractants, and inflammatory components in patients. Supervised and unsupervised analyses revealed a high abundance of CD177, a specific neutrophil activation marker, contributing to the clustering of severe patients. Gene abundance correlated with high serum levels of CD177 in severe patients. Higher levels were confirmed in a second cohort and in ICU than non-ICU patients (P< 0.001). Longitudinal measurements discriminated between patients with the worst prognosis, leading to death, and those who recovered (P = 0.01). These results highlight neutrophil activation as a hallmark of severe disease and CD177 assessment as a reliable prognostic marker for routine care.

9 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMatthieu Perreau
Matthieu Perreau
MSMadeleine Suffiotti
Madeleine Suffiotti
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
AWAurelie Wiedemann
Aurelie Wiedemann
YLYves Levy
Yves Levy
GPGiuseppe Pantaleo
Giuseppe Pantaleo
The objective of the present study was to identify biological signatures of severe coronavirus disease 2019 (COVID-19) predictive of admission in the intensive care unit (ICU). Over 170 immunological markers were investigated in a ‘discovery’ cohort (n = 98 patients) of the Lausanne University Hospital (LUH-1). Here we report that 13 out of 49 cytokines were significantly associated with ICU admission in the three cohorts (P < 0.05 to P < 0.001), while cellular immunological markers lacked power in discriminating between ICU and non-ICU patients. The cytokine results were confirmed in two ‘validation’ cohorts, i.e. the French COVID-19 Study (FCS; n = 62) and a second LUH-2 cohort (n = 47). The combination of hepatocyte growth factor (HGF) and C-X-C motif chemokine ligand 13 (CXCL13) was the best predictor of ICU admission (positive and negative predictive values ranging from 81.8% to 93.1% and 85.2% to 94.4% in the 3 cohorts) and occurrence of death during patient follow-up (8.8 fold higher likelihood of death when both cytokines were increased). Of note, HGF is a pleiotropic cytokine with anti-inflammatory properties playing a fundamental role in lung tissue repair, and CXCL13, a pro-inflammatory chemokine associated with pulmonary fibrosis and regulating the maturation of B cell response. Up-regulation of HGF reflects the most powerful counter-regulatory mechanism of the host immune response to antagonize the pro-inflammatory cytokines including CXCL13 and to prevent lung fibrosis in COVID-19 patients.

24 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
AWAurélie Wiedemann
Aurélie Wiedemann
EFEmile Foucat
Emile Foucat
HHHakim Hocini
Hakim Hocini
CLCécile Lefebvre
Cécile Lefebvre
BHBoris Hejblum
Boris Hejblum
YLYves Levy
Yves Levy
Long-term follow up studies from Ebola virus disease (EVD) survivors (EBOV_S) are lacking. Here, we evaluate immune and gene expression profiles in 35 Guinean EBOV_S from the last West African outbreak, a median of 23 months (IQR [18–25]) after discharge from treatment center. Compared with healthy donors, EBOV_S exhibit increases of blood markers of inflammation, intestinal tissue damage, T cell and B cell activation and a depletion of circulating dendritic cells. All survivors have EBOV-specific IgG antibodies and robust and polyfunctional EBOV-specific memory T-cell responses. Deep sequencing of the genes expressed in blood reveals an enrichment in ‘inflammation’ and ‘antiviral’ pathways. Integrated analyses identify specific immune markers associated with the persistence of clinical symptoms. This study identifies a set of biological and genetic markers that could be used to define a signature of “chronic Ebola virus disease (CEVD)”.

15 September 2013 in The Journal of Immunology
Verified
Journal Article
Closed access
MYMehwish Younas
Mehwish Younas
SHSophie Hüe
Sophie Hüe
CLChristine Lacabaratz
Christine Lacabaratz
AGAurélie Guguin
Aurélie Guguin
AWAurélie Wiedemann
Aurélie Wiedemann
YLYves Lévy
Yves Lévy
The heterogeneity of human regulatory T cells (Tregs) may explain the discrepancies between studies on Tregs in physiology and pathology. Contrasting effects of IL-7 on the expansion and survival of human Tregs were reported. Therefore, we investigated the effects of IL-7 on the phenotype and function of well-characterized populations of human Tregs. We show that IL-7 signals via the CD127 receptor on naive, memory, and activated memory Tregs sorted from the blood of healthy donors, but it does not affect their proliferation. In contrast, IL-7 affects their suppressive capacities differently. This effect was modest on naive Tregs but was dramatic (90%) on memory Tregs. We provide evidence that IL-7 exerts a synergistic effect through downmodulation of the ectoenzyme CD39, which converts ATP to ADP/AMP, and an increase in ATP receptor P2X7. Both effects lead to an increase in the ATP-mediated effect, tipping the balance to favor Th17 conversion. Using an IL-7 therapeutic study, we show that IL-7 exerts the same effects in vitro and in vivo in HIV-infected individuals. Globally, our data show that IL-7 negatively regulates Tregs and contributes to increase the number of tools that may affect Treg function in pathology.

1 April 2005 in Immunology Letters
Verified
Journal Article
Closed access
AWAurelie Wiedemann
Aurelie Wiedemann
SMSabina Müller
Sabina Müller
BFBenoit Favier
Benoit Favier
DPDoris Penna
Doris Penna
MGMartine Guiraud
Martine Guiraud
SVSalvatore Valitutti
Salvatore Valitutti